Semaglutide, Marketed as Ozempic and Wegovy, Reduces Risk of Cardiovascular Events in Type 2 Diabetes Patients
Semaglutide, a medication available under brand names like Ozempic and Wegovy, has been shown to reduce the risk of heart disease, stroke, heart attack, and death in adults diagnosed with type 2 diabetes. Originally approved for managing type 2 diabetes, semaglutide works by stimulating GLP-1 receptors in the pancreas, which increases insulin secretion, lowers blood sugar levels, and decreases glucagon release. It also slows stomach emptying, contributing to a feeling of fullness and reduced appetite. While Ozempic is primarily prescribed for type 2 diabetes, Wegovy is approved for weight management in obese or overweight adults, often those with co-existing conditions like type 2 diabetes, high blood pressure, or high cholesterol. The medication is administered via injection and should be used in conjunction with diet and exercise programs.
